{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T05:22:31Z","timestamp":1768713751910,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,30]],"date-time":"2015-10-30T00:00:00Z","timestamp":1446163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.jphs.2015.10.008","type":"journal-article","created":{"date-parts":[[2015,11,6]],"date-time":"2015-11-06T10:31:23Z","timestamp":1446805883000},"page":"210-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells"],"prefix":"10.1016","volume":"129","author":[{"given":"Yuming","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth K.W.","family":"To","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve C.F.","family":"Au-Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2015.10.008_bib1","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","article-title":"Molecular pathways: BCR-ABL","volume":"18","author":"Cilloni","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jphs.2015.10.008_bib2","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.jphs.2015.10.008_bib3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jphs.2015.10.008_bib4","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jphs.2015.10.008_bib5","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/sj.leu.2402555","article-title":"Insights from pre-clinical studies for new combination treatment regimens with the Bcr\u2013Abl kinase inhibitor imatinib mesylate (Gleevec\/Glivec) in chronic myelogenous leukemia: a translational perspective","volume":"16","author":"Rosee","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.jphs.2015.10.008_bib6","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.leukres.2015.02.013","article-title":"Celecoxib sensitizes imatinib-resistant K562 cells to imatinib by inhibiting MRP1\u20135, ABCA2 and ABCG2 transporters via Wnt and Ras signaling pathways","volume":"39","author":"Dharmapuri","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.jphs.2015.10.008_bib7","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1128\/JB.116.3.1247-1252.1973","article-title":"Effect of cis-platinum(II)diamminodichloride on wild type and deoxyribonucleic acid repair deficient mutants of Escherichia coli","volume":"116","author":"Beck","year":"1973","journal-title":"J\u00a0Bacteriol"},{"key":"10.1016\/j.jphs.2015.10.008_bib8","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00432-008-0408-0","article-title":"Novel treatment of ovarian cancer cell lines with imatinib mesylate combined with paclitaxel and carboplatin leads to receptor-mediated antiproliferative effects","volume":"134","author":"Mundhenke","year":"2008","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.jphs.2015.10.008_bib9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/cncr.21640","article-title":"Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma","volume":"106","author":"Johnson","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.jphs.2015.10.008_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-2-1","article-title":"Potentiates the cisplatin effect in\u00a0vitro","volume":"9","author":"Zhang","year":"2003","journal-title":"Mol Cancer"},{"key":"10.1016\/j.jphs.2015.10.008_bib11","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bcp.2009.06.014","article-title":"Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2","volume":"78","author":"Tanihara","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jphs.2015.10.008_bib12","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1158\/0008-5472.CAN-09-0548","article-title":"Imatinib mesylate induces cisplatin hypersensitivity in Bcr\u2013Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity","volume":"69","author":"Skorta","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.jphs.2015.10.008_bib13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/CAD.0b013e32834b72de","article-title":"The in-vitro antiproliferative effect of PRI-2191 and imatinib applied in combined treatment with cisplatin, idarubicin, or docetaxel on human leukemia cells","volume":"23","author":"\u015awitalska","year":"2012","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.jphs.2015.10.008_bib14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.jphs.2015.10.008_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"10.1016\/j.jphs.2015.10.008_bib16","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the chou-talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.jphs.2015.10.008_bib17","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR\u2013ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jphs.2015.10.008_bib18","doi-asserted-by":"crossref","first-page":"943","DOI":"10.4161\/cbt.5.8.2876","article-title":"Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter","volume":"5","author":"Helleman","year":"2006","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jphs.2015.10.008_bib19","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1038\/sj.leu.2402647","article-title":"Lack of p53 expression in human myeloid leukemias is not due to mutations in transcriptional regulatory regions of the gene","volume":"16","author":"Durland-Busbice","year":"2002","journal-title":"Leukemia"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861315002194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861315002194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T02:09:00Z","timestamp":1599790140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861315002194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1347861315002194"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2015.10.008","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2015.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}